Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Acrivon Therapeutics
- Study ID
- NCT06667141
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- Specific Advanced Solid Tumors
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- ACR-2316 — DRUGACR-2316 is an experimental drug
Study Details
This is a first in-human, Open-label Phase 1 study to assess the safety of ACR-2316 for the treatment of subjects with specific, histologically confirmed, locally advanced, recurrent or metastatic solid tumors.
Key Dates
- Start date
- Oct 8, 2024
- Status verified
- Mar 2026
- Primary completion
- Aug 12, 2026
- Completion
- Dec 12, 2026
Study Design
- Enrollment
- 100 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Dose escalationACR-2316 will be administered using a 3-week or a 4-week schedule.
- Experimental: Dose expansionACR-2316 will be administered using a 3-week or a 4-week schedule.
Primary Outcome Measure
Dose Escalation [ Time Frame: Number of DLT events during the DLT observation period (up to 28 days) ]
Central Contacts
- Mansoor R Mirza, MD617-207-8979
- Jeanie Tang
Locations (15)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| HonorHealth Research Institute | Phoenix | Arizona | 85016 | Amy Petersburg Lyndsay Willmott, MD (PRINCIPAL_INVESTIGATOR) |
| Precision NextGen Oncology & Research Center | Beverly Hills | California | 90212 | Francisco Capilla Kamlesh K Sankhala, MD (PRINCIPAL_INVESTIGATOR) |
| Hoag Memorial Hospital Presbyterian | Newport Beach | California | 92663 | Ariel Klingfus Monica Mita, MD (PRINCIPAL_INVESTIGATOR) |
| Denver Health One | Denver | Colorado | 80218 | Rachel Morgan Gerald Falchook, MD (PRINCIPAL_INVESTIGATOR) |
| Florida Cancer Specialist | Sarasota | Florida | 34232 | Mallory Hawkins Judy S Wang, MD (PRINCIPAL_INVESTIGATOR) |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | Victoria Weden Gerburg Wulf, MD (PRINCIPAL_INVESTIGATOR) |
| University of Michigan | Ann Arbor | Michigan | 48109 | Fatima Darwiche Zhen Ni Zhou, MD (PRINCIPAL_INVESTIGATOR) |
| Roswell Park Comprehensive Cancer Center | Buffalo | New York | 14203 | Paige Wierzbicki Katherine LaVigne Mager, MD (PRINCIPAL_INVESTIGATOR) |
| Montefiore Medical Centre | The Bronx | New York | 10461 | Sene Martin Nicole Nevadunsky, MD (PRINCIPAL_INVESTIGATOR) |
| Carolina BioOncology Institute | Huntersville | North Carolina | 28078 | Hannah Wall Neel Gandhi, MD (PRINCIPAL_INVESTIGATOR) |
| Rhode Island Hospital | Providence | Rhode Island | 02903 | Megan Faria Benedito Carneiro, MD (PRINCIPAL_INVESTIGATOR) |
| Tennessee Oncology | Franklin | Tennessee | 37067 | Catt Pecknold Jeff Russell, MD (PRINCIPAL_INVESTIGATOR) |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77054 | CR Registration Team Office of Clinical Research Timothy A Yap, MD,PhD (PRINCIPAL_INVESTIGATOR) |
| NEXT Oncology | San Antonio | Texas | 78229 | Jordan Georg David Sommerhalder, MD (PRINCIPAL_INVESTIGATOR) |
| Next Virginia | Fairfax | Virginia | 22031 | Blake Patterson Mohamad Salkeni, MD (PRINCIPAL_INVESTIGATOR) |